iPS cells and research
Approvals and research news on iPS cell-derived products. In 2026 Japan granted its first conditional, time-limited approvals to iPS cell-derived products; here we follow what that does and does not mean.
01What this topic covers
- What iPS cells are
- Conditional, time-limited approval
- Post-marketing surveillance
- Research updates
02The first conditional approvals, 2026
On 6 March 2026 the MHLW granted conditional, time-limited (7-year) approval to Sumitomo Pharma’s iPS cell-derived product for Parkinson’s disease (アムシェプリ) and to Cuorips’ product for severe heart failure (リハート), the first iPS cell-derived products to be approved. After conditional approval, post-marketing surveillance of every treated case is still required before full approval can be applied for.
Conditionally approved products like these fall under insurance and are not the same thing as a clinic’s self-pay treatments.
Source: Science Portal (JST), 18 March 2026; Sumitomo Pharma announcement; Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11
03Guides in this topic
iPS cells and researchJapan Approves the First iPS Cell–Derived Products: What Conditional Approval Means for PatientsJapan gave conditional, time-limited approval to two iPS cell products on 6 March 2026. Here is what the heart and Parkinson's approvals mean for patients.
iPS cells and researchWhat Are iPS Cells? Shinya Yamanaka's Discovery and the Yamanaka FactorsiPS cells are adult cells reprogrammed to a pluripotent state. Learn how Shinya Yamanaka made them, the four Yamanaka factors, the 2012 Nobel Prize and the 2026 approvals.